A Study of MK-1484 as Monotherapy and in Combination with Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Trial Identifier: 1484-001
Sponsor: MSD
Start Date: June 2022
Primary Completion Date: July 2026
Study Completion Date: July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Netherlands, Noord-Holland Amsterdam, Noord-Holland, Netherlands, 1066CX
Netherlands, Utrecht Utrecht, Netherlands, 3584 CX
Netherlands, Zuid-Holland Rotterdam, Zuid-Holland, Netherlands, 3015 GD
United States, SD Sioux falls, SD, United States, 57104
United States, TX San Antonio, TX, United States, 78229